form8k04242008.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported) April 24,
2008
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-23143
|
|
13-3379479
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
777 Old Saw Mill River
Road, Tarrytown, New York
|
|
10591
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code (914)
789-2800
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section
8 – Other Events
Item
8.01. Other Events.
Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), yesterday announced that the U.S. Food and Drug
Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide)
subcutaneous injection for the treatment of opioid-induced constipation in
patients with advanced illness who are receiving palliative care, when response
to laxative therapy has not been sufficient. The companies also announced that
they have received a Positive Opinion for RELISTOR subcutaneous injection from
the Committee for Medicinal Products for Human Use (CHMP), the scientific
committee of the European Medicines Agency (EMEA).
Copies of
these Progenics/Wyeth press releases are attached hereto as Exhibits 99.1 and
99.2 and the information contained therein is incorporated by reference into
this Item 8.01 of this Current Report on Form 8-K.
Progenics
also yesterday announced that its Board of Directors has approved a share
repurchase program to acquire up to $15 million of its outstanding common
shares, funding for which will come from the $15 million milestone payment
Progenics will receive from Wyeth for receiving FDA marketing approval for
RELISTOR for subcutaneous use. Purchases under the program will be made at the
company’s discretion and may be discontinued at any time. A copy of this
Progenics press release is attached hereto as Exhibit 99.3 and the information
contained therein is incorporated by reference into this Item 8.01 of this
Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
99.1
|
Press
Release dated April 24, 2008
|
99.2
|
Press
Release dated April 24, 2008
|
99.3
|
Press
Release dated April 24, 2008
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS
PHARMACEUTICALS, INC.
By: /s/ ROBERT A.
MCKINNEY
Robert A. McKinney
Chief Financial Officer, Senior
Vice President,
Finance &
Operations and Treasurer
Date: April 25,
2008